Federated Hermes, Inc. Spectrum Pharmaceuticals Inc Transaction History

Federated Hermes, Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.7 - $1.4 $3 - $7	-5 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$0.63 - $1.59 $3 - $7	5 New	5 $1,000
Q3 2021 Nov 15, 2021	SELL	$2.15 - $3.82 $64,820 - $115,169	-30,149 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$2.89 - $4.45 $43 - $66	-15 Reduced 0.05%	30,149 $113,000
Q1 2021 May 13, 2021	BUY	$2.9 - $4.09 $59,940 - $84,536	20,669 Added 217.68%	30,164 $98,000
Q4 2020 Feb 12, 2021	BUY	$3.38 - $5.14 $882 - $1,341	261 Added 2.83%	9,495 $32,000
Q3 2020 Nov 12, 2020	BUY	$2.99 - $4.9 $8,617 - $14,121	2,882 Added 45.37%	9,234 $38,000
Q2 2020 Aug 13, 2020	BUY	$2.11 - $3.38 $13,402 - $21,469	6,352 New	6,352 $21,000
Q1 2020 May 13, 2020	SELL	$1.83 - $3.45 $1,110 - $2,094	-607 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$3.5 - $10.35 $143 - $424	-41 Reduced 6.33%	607 $2,000
Q3 2019 Nov 14, 2019	BUY	$7.03 - $9.7 $344 - $475	49 Added 8.18%	648 $5,000
Q2 2019 Aug 14, 2019	BUY	$7.36 - $11.26 $4,254 - $6,508	578 Added 2752.38%	599 $5,000
Q3 2018 Nov 13, 2018	SELL	$16.52 - $24.82 $19,196 - $28,840	-1,162 Reduced 98.22%	21 $1,000
Q3 2017 Nov 13, 2017	BUY	$8.75 - $14.07 $10,351 - $16,644	1,183	1,183 $17,000

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.